Molecular and genetic aspects of lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 4 I, 2000, Pages 1355-1367

  Rom, William N ^a   Hay, John G ^a   Lee, Theodore C ^a   Jiang, Yixing ^a   Tchou Wong, Kam Meng ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CHROMOSOME ABERRATION; CIGARETTE SMOKING; GENE ACTIVATION; GENE THERAPY; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034058527     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.4.9908012     Document Type: Review

References (169)

1. Nesbitt, J. C., J. B. Putnam, Jr., G. L. Walsh, J. A. Roth, and C. F. Mountain. 1995. Survival in early-stage lung cancer. Ann. Thorac. Surg. 60: 466-472.
2. Miller, J. A., and O. R. Jones. 1930. Primary carcinoma of the lung. Am. Rev. Tuberc. 21:1-56.
3. Ochsner, M., and M. DeBakey. 1939. Symposium on cancer. Primary pulmonary malignancy. Treatment by total pneumonectomy: analyses of 79 collected cases and presentation of 7 personal cases. Surg. Gynecol. Obstet. 68:435-451.
4. Weiss, W., H. Seidman, and K. R. Boucot. 1978. The Philadelphia pulmonary neoplasm research project: symptoms in occult lung cancer. Chest 73:57-61.
5. Sridhar, K. S., C. F. Lobo, and R. D. Altman. 1998. Digital clubbing and lung cancer. Chest 114:1535-1537.
6. Mountain, C. F. 1997. Revisions in the International System for staging lung cancer. Chest 111:1710-1717.
7. ATS/ERS Statement. 1997. Pretreatment evaluation of non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 156:320-332.
8. Shaw, G. L., R. T. Falk, L. W. Pickle, T. J. Mason, and D. A. Buffler. 1991. Lung cancer risk associated with cancer in relatives. J. Clin. Epidemiol. 44:429-437.
9. Saraceno, J., and S. D. Spivack. 1999. Strategies for early detection of lung cancer. Clin. Pulm. Med. 6:66-72.
10. Henschke, C. I., D. I. McCauley, D. F. Yankelevitz, et al. 1999. Early lung cancer action project: overall design and findings from baseline screening. Lancet 354:99-105.
11. Kennedy, T. C., S. P. Proudfoot, W. A. Franklin, et al. 1996. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res. 56:4673-4678.
12. Tockman, M. S., J. L. Mulshine, S. Piantadosi, et al. 1997. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3:2237-2246.
13. Tockman, M. S., P. K. Gupta, J. D. Myers, et al. 1988. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J. Clin. Oncol. 6:1685-1693.
14. Payne, P. W., T. J. Sebo, A. Doudkine, et al. 1997. Sputum screening by quantitative microscopy: a re-examination of a portion of the NCI Cooperative Early Lung Cancer Study. Mayo. Clin. Proc. 72:697-704.
15. Lam, S., C. MacAulay, J. Hung, J. LeRiche, A. E. Profio, and B. Palcic. 1993. Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscopy (LIFE) device. J. Thorac. Cardiovasc. Surg. 105:1035-1040.
16. Lam, S., T. Kennedy, M. Unger, et al. 1998. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113:696-702.
17. Kurie, J. M., J. S. Lee, R. C. Morice, G. L. Walsh, F. R. Khuri, A. Broxson, J. Y. Ro, W. A. Franklin, R. Yu, and W. K. Hong. 1998. Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J. Natl. Cancer Inst. 90:991-995.
18. Collisharv, N. E., and A. D. Lopez. 1996. The Tobacco Epidemic: A Global Public Health Emergency. Tobacco Alert, World Health Organization, Geneva.
19. Doll, R., and A. B. Hill. 1954. The mortality of doctors in relation to their smoking habits: a preliminary report. Br. Med. J. 1:1451-1455.
20. Hammond, E. C., and D. Horn. 1954. The relationship between human smoking habits and death rates: a follow-up study of 187,766 men. J.A.M.A. 155:1316-1328.
21. Thun, M. J., C. A. Day-Lalley, E. E. Calle, W. D. Flanders, and C. A. Heath. 1995. Excess mortality among cigarette smokers: changes in a 20-year interval. Am. J. Public Health 85:1223-1230.
22. Doll, R., R. Peto, K. Wheatley, R. Gray, and I. Sutherland. 1994. Mortality in relation to smoking: 40 years' observations on male British doctors. Br. Med. J. 309:901-911.
23. Hirayama, T. 1981. Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan. Br. Med. J. 282:183-185.
24. Trichopoulos, D., A. Kalandida, L. Sparros, and B. MacMahon. 1981. Lung cancer and passive smoking. Int. J. Cancer 23:803-807.
25. Harris, R. E., E. A. Zang, J. I. Anderson, and E. L. Wynder. 1993. Race and sex differences in lung cancer risk associated with cigarette smoking. Int. J. Epidemiol. 22:592-599.
26. Ryberg, D., A. Hewer, D. H. Phillips, and A. Haugen. 1994. Different susceptibility to smoking induced DNA damage among male and female lung cancer patients. Cancer Res. 54:5801-5803.
27. Fielding, J. E. 1985. Smoking: health effects and control. N. Engl. J. Med. 313:491-498, 555-562.
28. Thun, M. J., C. A. Lally, J. T. Flannery, E. E. Calle, W. D. Flanders, and C. W. Heath. 1997. Cigarette smoking and changes in the histopalhology of lung cancer. J. Natl. Cancer Inst. 89:1580-1586.
29. Pershagen, G., G. Akerblom, O. Axelson, et al. 1994. Residential radon exposure and lung cancer in Sweden. N. Engl. J. Med. 330:159-164.
30. Hammond, E. C., I. J. Selikoff, and H. Seidman. 1979. Asbestos exposure, cigarette smoking, and death rates. Ann. N.Y. Acad. Sci. 330: 473-490.
31. Hecht, S. S. 1998. Cigarette smoking and cancer. In W N. Rom, editor. Environmental and Occupational Medicine, 3rd ed. Lippincott-Raven, Philadelphia. 1479-1500.
32. Spivack, S. D., M. J. Fasco, V. E. Walker, and L. S. Kaminsky. 1997. The molecular epidemiology of lung cancer. Crit. Rev. Toxicol. 27: 319-365.
33. Wei, Q., L. Cheng, W. K. Hong, and M. R. Spitz. 1996. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 56:4103-4107.
34. Wuerin, J., and P. Nurse. 1996. Regulating S phase: CDKs, licensing and proteolysis. Cell 85:785-787.
35. Sherr, C. 1996. Cancer cell cycles. Science 274:1672-1677.
36. Hunter, T., and J. Pines. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
37. Schaur, E. I., S. Siriwardana, T. A. Langan, and R. A. Sciafani. 1994. Cyclin D1 overexpression vs retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc. Natl. Acad. Sci. U.S.A. 91:7827-7831.
38. Weintraub, S. J. 1996. Inactivation of tumor suppressor proteins in lung cancer. Am. J. Respir. Cell Mol. Biol. 15:150-155.
39. El-Deiry, W. S., T. Tokino, V. E. Velculescu, et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
40. Nevins, J. R. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-129.
41. Barak, Y., T. Juven, R. Haffner and M. Oren. 1993. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-168.
42. Stillman, B. 1996. Cell cycle control of DNA replication. Science 274: 1659-1663.
43. Sanders Williams, R., R. V. Shohet, and B. Stillman. 1997. A human protein related to yeast Cdc6p. Proc. Natl. Acad. Sci. U.S.A. 94:142-147.
44. Yan, Z., J. DeGregori, R. Shohet, et al. 1998. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 95:3603-3608.
45. Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumour suppressor gene. Nature 351:453-456.
46. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
47. Prives, C. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:1437-1443.
48. Weinberg, R. A. 1991. Tumor suppressor genes. Science 254:1138-1146.
49. Knudson, A. G. 1993. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A. 90:10914-10921.
50. Tchou, W. W., W. N. Rom, and K. M. Tchou-Wong. 1996. Novel form of p21 WAF1/C1P1/SC11 protein in phorbol ester-induced G2/M arrest. J. Biol. Chem. 271:29556-29560.
51. Ramet, M., K. Casten, K. Jarvinen, et al. 1996. P53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16:2117-2124.
52. Denissenko, M. F., A. Pao, M. Tang, and G. P. Pfeifer. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430-432.
53. Denissenko, M. F., J. Y. Chen, M. S. Tang, and G. P. Pfeifer. 1997. Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc. Natl. Acad. Sci. U.S.A. 94:3893-3898.
54. Chen, J. X., Y. Zheng, M. West, and M. Tang. 1998. Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res. 58:2070-2075.
55. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578.
56. Smith, M. L., I.-T. Chen, Q. Zhan, et al. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380.
57. Zambetti, G., and A. J. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:855-865.
58. Werner, H., E. Karnieli, F. J. Rauscher, III, and D. LeRoith. 1996. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. U.S.A. 93:8318-8323.
59. Jiang, Y., W. N. Rom, T. A. Yie, C. X. Chi, and K. M. Tchou-Wong. 1999. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 18:6071-6077.
60. Kamb, A., N. A. Gruis, J. Weaver-Feldhaus, et al. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
61. Cairns, P., T. J. Polascik, Y. Eby, et al. 1995, Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat. Genet. II: 210-212.
62. Okamoto, A., S. P. Hussain, K. Hagiwara, et al. 1995. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55:1448-1451.
63. INK4B and p18 genes in primary non-small-cell lung cancers. Int. J. Cancer 65:734-739.
64. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. U.S.A. 95: 11891-11896.
65. Michalides, R. J. A. M. 1998. Deregulation of the cell cycle in lung cancer. In C. Brambilla and E. Brambilla, editors. Lung Biology in Health and Disease. Marcel Dekker, New York. 211-225.
66. ARF. Cell 91:555-558.
67. Harbour, J. W., S. L. Lai, J. Whang-Peng, et al. 1988. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357.
68. INK4 expression in primary lung cancers and cell lines. Cancer Res. 55:505-509.
69. Kelley, M. J., K. Nakagawa, S. M. Steinberg, J. L. Mulshine, A. Kamb, and B. E. Johnson. 1995. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J. Natl. Cancer Inst. 87:756-761.
70. Gorgoulis, V. G., P. Zacharatos, A. Kotsinas, et al. 1998. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas. Am. J. Path. 153:1749-1765.
71. ARF links the tumour suppressors RB and p53. Nature 395:124-125.
72. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Devel. 12:2424-2433.
73. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
74. Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Nat. Acad. Sci. U.S.A. 95:8292-8297.
75. Zhang, Y., and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3:579-591.
76. INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 58:3926-3931.
77. 4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261.
78. Kim, S. J., S. Wagner, F. Lin, M. A. O'Reilly, P. D. Robbins, and M. R. Green. 1992. Retinoblastoma gene product activates expression of the human TGF-β2 gene through transcription factor ATF-2. Nature 358:331-334.
79. Li, C.-Y., L. Suardet, and J. R. Little. 1995. Potential role of WAF1/Cip/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem. 270:4971-4974.
80. Iavarone, A., and J. Massague. 1997. Repression of the CDK activator Cdc 25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387:417-421.
81. INK4a,TGFβ, and contact inhibition. Cell 97:53-61.
82. Mills, N. E., C. L. Fishman, W. N. Rom, N. Dubin, and D. R. Jacobson. 1995. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 55:1444-1447.
83. Mills, N. E., C. L. Fishman, J. Scholes, S. E. Anderson, W. N. Rom, and D. R. Jacobson. 1995. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid as a diagnostic test for lung cancer. J. Natl. Cancer. Inst. 87:1056-1060.
84. Slebos, R. J. C., R. E. Kibbelaar, O. Dalesio, et al. 1990. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 9:561-565.
85. Zhang, Y., T. Mukhopadhyay, L. A. Donehower, R. N. Georges, and J. A. Roth. 1993. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum. Gene Ther. 4:451-460.
86. Moodie, S. A., B. M. Willumsen, M. J. Weber, and A. Wolfman. 1993. Complexes of ras-GTP with raf-1 and mitogen-activated protein kinase. Science 260:1658-1661.
87. Li, Z. H., J. Zheng, L. M. Weiss, and D. Shibata. 1994. K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol. 144:303-309.
88. Agarwal, M. L., W. R. Taylor, M. V. Chernov, O. B. Chernova, and G. R. Stark. 1998. The p53 network. J. Biol. Chem. 273:1-4.
89. Leone, G., J. DeGregori, R. Sears, L. Jakoi, and J. R. Nevins. 1997. Myc and ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387:422-426.
90. Peeper, D. S., T. M. Upton, M. Ladha, et al. 1997. Ras signaling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386:177-181.
91. Sears, R., G. Leone, J. DeGregori, and J. R. Nevins. 1999. Ras enhances myc protein stability. Mol. Cell 3:169-179.
92. ink4. Science 267:249-252.
93. WAF1/C1P1. Nature 394:295-299.
94. ARF links the tumour suppressor p53 to ras. Nature 395:125-126.
95. Kamijo, T., S. Bodner, E. van de Kamp, D. H. Randle, and C. J. Sherr. 1999. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:2217-2222.
96. Galaktionov, K., X. Chen, and D. Beach. 1996. Cdc25 cell-cycle phosphatase as a target of c-myc. Mature 382: 511-517.
97. Hunter, T. 1997. Oncoprotein networks. Cell 88:333-346.
98. Lee, T. C., and E. B. Ziff. 1999. Mxi1 is a repressor of the c-myc promoter and reverses activation by USF. J. Biol. Chem. 274:595-606.
99. Lee, T. C., L. Li, L. Philipson, and E. B. Ziff. 1997. Myc represses transcription of the growth arrest gene gas1. Proc. Natl. Acad. Sci. U.S.A. 94:12886-12891.
100. Marhin, W. W., S. Chen, L. M. Facchini, A. J. Fornace, Jr., and L. Z. Penn. 1997. Myc represses the growth arrest gene gadd45. Oncogene 14:2825-2834.
101. Del Sal, G., E. M. Ruaro, R. Utrera, C. N. Cole, A. J. Levine, and C. Schneider. 1995. Gas1-induced growth suppression requires a trans-activation-independent p53 function. Mol. Cell. Biol. 15:7152-7160.
102. Viallet, J., and J. Minna. 1990. Dominant oncogenes and tumor suppressor genes in the pathogenesis of human lung cancer. Am. J. Respir. Cell Mol. Biol 2:225-232.
103. Broers, J. L. V., J. Viallet, S. M. Jensen, H. Pass, W. D. Travis, J. D. Minna, and R. I. Linnoila. 1993. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am. J. Respir. Cell Mol. Biol. 9:33-43.
104. Gazzeri, S., E. Brambilla, C. Caron de Fromentel, V. Bouyer, D. Moro, P. Perron, F. Berger, and C. Brambilla. 1994. p53 genetic abnormalities and myc activation in human lung carcinoma. Int. J. Cancer 58:24-32.
105. Franklin, W. A., A. F. Gazdar, J. Haney, et al. 1997. Widely dispersed p53 mutation in respiratory epithelium: a novel mechanism for field carcinogenesis. J. Clin. Invest. 100:2133-2137.
106. Auerbach, O. C., C. Hammond, and L. Garfinkel. 1979. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs 1970-1977. N. Engl. J. Med. 300:381-386.
107. Saccomanno, G., V. E. Archer, O. Auerbach, R. P. Saunders, and L. U. Brennan. 1974. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 33:256-270.
108. Risse, E. K. J., G. P. Vooijs, and M. A. van't Hof. 1988. Diagnostic significance of 'severe dysplasia' in sputum cytology. Acta Cytol. 32:629-634.
109. Keith, R. L., M. Varella-Garcia, R. M. Gemmill, et al. 1998. Morphologic and genetic abnormalities in the bronchial epithelium of high risk smokers (abstract). Am. J. Respir. Crit. Care Med. 157:692A.
110. Hung, J. Y., Y. Kishimoto, K. Sugio, et al. 1995. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J.A.M.A. 273:558-563.
111. Sozzi, G., M. L. Veronese, M. Negrini, et al. 1996. Th FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85:17-26.
112. Fong, K. M., E. J. Biesterveld, A. Virmani, et al. 1997. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 57:2256-2267.
113. Sozzi, G., L. Sard, L. DeGregorio, et al. 1997. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57:2121-2123.
114. Burke, L., M. A. Khan, A. N. Freedman, et al. 1998. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res. 58:2533-2536.
115. Siprashvili, Z., G. Sozzi, L. D. Barnes, et al. 1997. Replacement of FHIT in cancer cells suppressed tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 94:13771-13776.
116. Bennett, W. P., T. V. Colby, W. D. Travis, et al. 1993. P53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 53:4817-4822.
117. Maitra, A., I. I. Wistuba, A. K. Virmani, M. Sakaguchi, I. Park, A. Stucky, S. Milchgrub, D. Gibbons, J. D. Minna, and A. F. Gazdar. 1999. Enrichment of epithelial cells for molecular studies. Nature Med. 5:459-463.
118. Gerwin, B. I., E. Spillare, K. Forrester, et al. 1992. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β1. Proc. Natl. Acad. Sci. U.S.A. 89:2759-2763.
119. Mao, L., J. S. Lee, J. M. Kure, et al. 1997. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89: 857-862.
120. Wistuba, I. I., S. Lam, C. Behrens, A. Virmani, K. Fong, J. LeRiche, J. Samet, S. Srivastave, J. Minna, and A. Gazdar. 1997. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89:1366-1373.
121. Kishimoto, Y., K. Sugio, J. Y. Hung, et al. 1995. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J. Natl Cancer Inst. 87:1224-1229.
122. INK4-Cyclin D1) in preinvasive bronchial lesions. Clin. Cancer Res. 5:243-250.
123. Lonardo, F., V. Rusch, J. Lagenfeld, E. Dmitrovsky, and D. S. Klimstra. 1999. Overexpression of Cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 59:2470-2476.
124. Westra, W., R. Slebos, G. Offerhaus, et al. 1994, K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer 72:432.
125. Mao, L., R. Hruban, J. Boyle, et al. 1994. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54: 1634.
126. Wistuba, I. I., C. Behrens, S. Milchgrub, D. Bryant, J. Hung, J. D. Minna, and A. F. Gazdar. 1999. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18:643-650.
127. van Steensel, B., and T. de Lange. 1998. Control of telomere length by the human telomeric protein TRF1. Nature 385:740-743.
128. Hayflick, L. and P. S. Moorhead. 1961. The serial cultivation of human diploid cells strains. Exp. Cell Res. 25:585-621.
129. Chin, L., S. E. Artandi, Q. Shen, A. Tam, S. L. Lee, G. J. Gottlieb, C. W. Greider, and R. A. DePinho. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527-538.
130. Bodnar, A. G., M. Ouellette, M. Frolkis, S. E. Holt, C. P. Chiu, G. B. Morin, C. B. Harley, J. W. Shay, S. Lichsteiner, and W. E. Wright. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352.
131. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396:84-88.
132. Δ2/3 cancer-prone mouse. Cell 97:515-525.
133. Hiyama, K., E. Hiyama, S. Ishioka, M. Yamakido, K. Inai, A. F. Gazdar, M. A. Piatyszek, and J. W. Shay. 1995. Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl. Cancer Inst. 87: 895-902.
134. Albanell, J., F. Lonardo, V. Rusch, M. Engelhardt, J. Langenfeld, W. Han, D. Klimstra, E. Venkatraman, M. A. Moore, and E. Dmitrovshky. 1997. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J. Natl. Cancer Inst. 89:1609-1615.
135. Yahata, N., K. Ohyashiki, J. H. Ohyashiki, et al. 1998. Telomerase activity in lung cancer cells obtained from bronchial washings. J. Natl. Cancer Inst. 90:684-690.
136. Arai, T., Y. Yasuda, T. Takaya, Y. Ito, K. Hayakawa, S. Toshima, C. Shibuya, N. Yoshimi, and Y. Kashiki. 1998. Application of telomerase activity for screening of primary lung cancer in broncho-alveolar lavage fluid. Oncol. Reports 5:405-408.
137. Yashima, K., L. A. Litzky, L. Kaiser, et al. 1997. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 57:2373-2377.
138. Wikenheiser, K. A., J. C. Clark, R. I. Linnoila, et al. 1992. Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produced pulmonary adenocarcinomas in transgenic mice. Cancer Res. 52:5342.
139. Magdaleno, S. M., G. Wang, V. L. Mireles, M. K. Ray, M. J. Finegold, and F. DeMayo. 1997. Cyclin-dependent kinase inhibitor expression in pulmonary clara cells transformed with SV40 large T antigen in transgenic mice. Cell Growth Differentia. 8:145-155.
140. Jacks, T., L. Remington, B. Williams, E. Schmitt, S. Halachmi, R. Bronson, and R. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
141. Harvey, M., H. Vogel, E.Y.-H.P. Lee, A. Bradley, and L. A. Donehower. 1995. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 55:1146-1151.
142. Williams, B. O., L. Remington, D. M. Albert, S. Mukai, R. T. Bronson, and T. Jacks. 1995. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet. 7:481-484.
143. Wikenheiser, K. A., and J. A, Whitsett. 1997. Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice. Am. J. Respir. Cell Mol. Biol. 16:713-723.
144. Jiang, Y., C. Chi, K. M. Tchou-Wong, A. Pellicer, and W. N. Rom. 1998. Lung specific expression of a dominant negative mutant of p53 in transgenic mice (abstract). Am. J. Respir. Crit. Care Med. 157:A321.
145. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. De-Pinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
146. Hecht, S. S., S. Isaacs, and N. Trushin. 1994. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo(a)pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis 15: 2721-2725.
147. Mass, M. J., A. J. Jeffers, J. A. Ross, G. Nelson, A. J. Galati, G. D. Stoner, and S. Nesnow. 1993. Ki-ras oncogene mutations in tumors and DNA adducts formed by benz(j)aceanthrylene and benzo(a)pyrene in the lungs of strain A/J mice. Mol. Carcinogen. 8:186-192.
148. Conry, R. M., S. A. White, P. N. Fultz, et al. 1998. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin. Cancer Res. 4:2903-12.
149. Yang, N. S., and W. H. Sun. 1995. Gene gun and other non-viral approaches for cancer gene therapy. Nature Med. 1:481-483.
150. Cassileth, P. A., E. Podack, K. Sridhar, N. Savaraj, and J. Hanlon. 1995. Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum. Gene Ther. 6:369-383.
151. Zou, Y., G. Gong, Y. H. Ling, M. M. Hao, G. Lozano, W. K. Hong, and R. Perez-Soler. 1998. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J. Natl. Cancer Inst. 90:1130-1137.
152. Michael, S. I., J. S. Hong, D. T. Curiel, and J. A. Engler. 1995. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 2:660-668.
153. Dimitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-9713.
154. Krasnykh, V., I. Dmitriev, G. Mikheeva, C. R. Miller, N. Belousova, and D. T. Curiel. 1998. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72:1844-1852.
155. Smith, M. J., M. D. Rousculp, K. T. Goldsmith, D. T. Curiel, and R. I. Garver, Jr. 1994. Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum. Gene Ther. 5:29-35.
156. Rusch, V., J. Baselga, C. Cordon-Cardo, et al. 1993. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:2379-2385.
157. Kern, J. A., R. J. C. Slebos, B. Top, S. Rodenhuis, D. Lager, R. A. Robinson, D. Weiner, and D. A. Schwartz. 1994. C-erftB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest. 93:516-520.
158. Deshane, J., G. P. Siegal, R. D. Alvarez, M. H. Wang, M. Feng, G. Cabrera, T. Liu, M. Kay, and D. T. Curiel. 1995. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96:2980-2989.
159. Grim, J., J. Deshane, M. Feng, A. Lieber, M. Kay, and D. T. Curiel. 1996. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells. Am. J. Respir. Cell Mol. Biol. 15:348-354.
160. Ohno, K., K. Sawai, Y. Iijima, B. Levin, and D. Meruelo. 1997. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nature Biotechnol. 15:763-767.
161. Bischoff, J., D. Kirn, A. Williams, et al. 1996. An adenovinis mutant that replicates selectively in p53 deficient human tumor cells. Science 274:373-376.
162. Roth, J. A., D. Nguyen, D. D. Lawrence, et al. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:985-991.
163. Schuler, M., C. Rochlitz, J. A. Horowitz, et al. 1998. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. 9:2075-2082.
164. Kauczor, H. U., M. Schuler, C. P. Heussel, A. von Weymarn, G. Bongartz, C. Rochlitz, C. Huber, and M. Thelen. 1999. CT-guided intratumoral gene therapy in non-small-cell lung cancer. Eur. Radiol. 9:292-296.
165. Swisher, S. G., J. A. Roth, J. Nemunaitis, et al. 1999. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91:763-771.
166. Tursz, T., A. L. Cesne, P. Baldeyrou, et al. 1996. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J. Natl. Cancer Inst. 88:1857-1863.
167. Gahery-Segard, H., V. Molinier-Frenkel, C. Le Boulaire, et al. 1997. Phase I trial of recombinant adenovirus gene transfer in lung cancer: longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest. 100:2218-2226,
168. Sterman, D. H., J. Treat, L. A. Litzky, et al. 1998. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9:1083-1092.
169. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1:27-31.